Disc Medicine Completes Key Phase 1b Study of DISC-0974 in CKD Anemia: What Investors Should Watch

Disc Medicine, Inc. (IRON) announced an update on their ongoing clinical study.

Disc Medicine, Inc. (IRON) has completed a Phase 1b trial titled “A Phase 1b Multicenter, Randomized, Double-Blind, Placebo-Controlled Ascending Dose Study” of DISC-0974 in adults with chronic kidney disease (CKD) and anemia. The study tested safety and how the drug moves and acts in the body, an important early step for a new anemia treatment in non-dialysis CKD patients.

The drug under study, DISC-0974, is an injectable medicine given under the skin. It is designed to improve anemia in CKD by targeting pathways that control red blood cell production and iron use, offering a possible alternative to existing anemia drugs.

The trial was an interventional study where participants were randomly assigned to receive either DISC-0974 or a placebo. It used a double-blind setup, meaning patients, doctors, and outcome assessors did not know who received the drug, and the main goal was to test treatment safety rather than measure long-term benefits.

The plan included both single-dose and multiple-dose groups for DISC-0974 and matching placebo injections. This step-by-step dose approach helped the team observe safety signals and dose response over time while keeping the design controlled and comparable between treatment and placebo arms.

The study was first submitted on February 16, 2023, signaling the formal launch of the clinical program in this CKD population. The last update was filed on April 21, 2026, indicating that key data and status information were recently refreshed for investors and regulators.

The overall status is listed as completed, which means all planned dosing and follow-up have finished. The primary completion date marks when main outcome data were collected, while the estimated completion date covers all final analyses and reporting, important timing markers for upcoming data readouts.

For investors, the completion of this Phase 1b study reduces some early-stage risk for IRON by providing a safety and tolerability profile in real CKD patients. Positive results could support a move into larger efficacy trials and strengthen the company’s position in the growing anemia market tied to kidney disease.

The CKD anemia space includes established players in erythropoiesis-stimulating agents and newer hypoxia-inducible factor drugs, so any sign that DISC-0974 offers a safer or more convenient option could lift sentiment. Conversely, safety issues or modest effects could pressure the stock, especially given investor expectations around differentiated mechanisms in this crowded field.

With this trial completed and the record recently updated, investors should watch for top-line data, management commentary, and any partnering signals as near-term catalysts. The study is now in the data-reporting phase, and further details are available on the ClinicalTrials.gov portal.

To learn more about IRON’s potential, visit the Disc Medicine, Inc. drug pipeline page.